In conclusion, LINC01089 plays a tumor-suppressive role in malignant progression by inhibiting miR-27b-3p and increasing FBLN5 protein, confirming that LINC01089 has tremendous potential for use in the treatment of thyroid cancer. This evidence concerns the gene FBLN5 and neoplasm.